Article
Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.
Leukemia & lymphoma - 1 Jul 2016
Smirnikhina Svetlana A, Lavrov Alexander V, Chelysheva Ekaterina Yu, Adilgereeva Elmira P, Shukhov Oleg A, Turkina Anna, Kutsev Sergey I
Abstract excerpt
Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep molecular remission. Patients were divided into two groups with relapse (n = 3) and without relapse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.